Last reviewed · How we verify
NCT05007548
to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve
Phase 2 trial testing Ga68-Dolacga Injection in Hepatic Carcinoma in 30 participants. Completed in 20 November 2023.
20 November 2023
Quick facts
| Lead sponsor | National Atomic Research Institute, Taiwan |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 30 |
| Start date | 14 December 2021 |
| Primary completion | 20 November 2023 |
| Estimated completion | 20 November 2023 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Ga68-Dolacga Injection — full drug profile →
Conditions studied
- Hepatic Carcinoma — all drugs for Hepatic Carcinoma →
Sponsor
National Atomic Research Institute, Taiwan
Who can join
20 and older, any sex, with Hepatic Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a phase 2 open-labeled study to compare the Ga68-Dolacga positron emission tomography with computer tomography volumetry and indocyanine green retention test for measurement of liver reserve among scheduled surgery operation patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05007548
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ga68-Dolacga Injection
Trials testing the same drug.
- NCT03908957 — to Assess the Safety of Ga68-Dolacga Injection in Healthy Volunteers · Phase 1 · completed
Other recruiting trials for Hepatic Carcinoma
Currently open trials in the same condition.
- NCT07359586 — Laryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia · recruiting
- NCT06342414 — An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer · recruiting
- NCT04220944 — Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. · Phase 1 · active not recruiting
Other National Atomic Research Institute, Taiwan trials
Trials by the same sponsor.
- NCT06182865 — A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy · NA · unknown
- NCT03908957 — to Assess the Safety of Ga68-Dolacga Injection in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05007548 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Atomic Research Institute, Taiwan
- Last refreshed: 13 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05007548.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing